Dr. Hellmann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 E 66th St
New York, NY 10065Phone+1 617-726-2862
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Massachusetts General HospitalResidency, Internal Medicine, 2008 - 2011
Johns Hopkins University School of MedicineClass of 2008
Certifications & Licensure
NY State Medical License 2011 - 2026
NJ State Medical License 2020 - 2023
Clinical Trials
- Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies Start of enrollment: 2019 Mar 08
- Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors Start of enrollment: 2020 Feb 25
Publications & Presentations
PubMed
- 5693 citationsMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerNaiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov
Science. 2015-04-03 - 2130 citationsNivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenMatthew D. Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong-Seok Lee, Gregory A. Otterson
The New England Journal of Medicine. 2018-04-16 - 238 citationsSafety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.Fernando C. Santini, Hira Rizvi, Andrew J. Plodkowski, Andy Ni, Mario E. Lacouture
Cancer Immunology Research. 2018-09-01
Lectures
- Molecular circulating tumor DNA response to identify long-term survival in patients receiving immunotherapy with initial radiologic stable disease.2019 ASCO Annual Meeting - 6/1/2019
- A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors.2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
Damon Runyon Cancer Research Foundation Awards $4.8 Million to Rising InvestigatorsJuly 15th, 2021- Memorial Sloan Kettering Awards and AppointmentsAugust 17th, 2020
- The Pershing Square Foundation Awards $3 Million to Innovative SARS-CoV-2 Research ProjectsJuly 7th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
